The Clinical Trials Core Facility (CTCF) facilitates clinical research at the Case CCC by providing the highest quality infrastructure that includes nursing, regulatory, data management, quality assurance, budgeting and contracting, informatics, and education functions for research staff and investigators. With its expertise in coordinating and managing complex studies including early phase and investigator-initiated trials, the CTCF plays a central role in Case CCC clinical research. The CTCF resides within the Case CCC Clinical Research Office (CRO). The CRO oversees and coordinates all clinical research administration components including the CTCF, Protocol Review and Monitoring System, Data and Safety Monitoring, and Protocol Specific Research Support. As a consortium cancer center, the CTCF oversees operations at the affiliated medical centers, through the Clinical Trials Unit (CTU) at each hospital which is responsible for the development, conduct, and management of specific clinical trials. All training and audits are coordinated through the CTCF. The Medical Director of the CTCF oversees integration of activities of the consortium member CTUs, with standardization ensured through a single policies and procedures manual and monthly meetings of the Clinical Research Operations Committee (C-ROC) and its subcommittee, the Clinical Trials Working Group (CTWG). In 2011, 1,527 patients were enrolled onto Case CCC interventional trials, including 919 patients on therapeutic studies. Thirty-eight percent of accruals to therapeutic intervention studies were to investigator-initiated trials (peer-reviewed, institutional). The CTCF provides support for all cancer clinical trials, from protocol development through reporting of results. The Core also oversees use of the OnCore clinical trials database, ensuring timely maintenance of protocol status and patient accrual.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Zhao, S; Sedwick, D; Wang, Z (2015) Genetic alterations of protein tyrosine phosphatases in human cancers. Oncogene 34:3885-94|
|Dermawan, Josephine Kam Tai; Gurova, Katerina; Pink, John et al. (2014) Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-?B, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther 13:2203-14|
|Brubaker, Douglas; Difeo, Analisa; Chen, Yanwen et al. (2014) Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance. Pac Symp Biocomput :125-35|
|Yori, Jennifer L; Lozada, Kristen L; Seachrist, Darcie D et al. (2014) Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res 74:4762-71|
|Dabir, Snehal; Kluge, Amy; McColl, Karen et al. (2014) PIAS3 activates the intrinsic apoptotic pathway in non-small cell lung cancer cells independent of p53 status. Int J Cancer 134:1045-54|
|Zapanta Rinonos, Serendipity; Rai, Urvashi; Vereb, Sydney et al. (2014) Sequential logic of polarity determination during the haploid-to-diploid transition in Saccharomyces cerevisiae. Eukaryot Cell 13:1393-402|
|Sizemore, Gina M; Sizemore, Steven T; Seachrist, Darcie D et al. (2014) GABA(A) receptor pi (GABRP) stimulates basal-like breast cancer cell migration through activation of extracellular-regulated kinase 1/2 (ERK1/2). J Biol Chem 289:24102-13|
|Sossey-Alaoui, Khalid; Pluskota, Elzbieta; Davuluri, Gangarao et al. (2014) Kindlin-3 enhances breast cancer progression and metastasis by activating Twist-mediated angiogenesis. FASEB J 28:2260-71|
|Dotan, Efrat; Devarajan, Karthik; D'Silva, A James et al. (2014) Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. Clin Colorectal Cancer 13:192-8|
|Arachiche, Amal; de la Fuente, María; Nieman, Marvin T (2014) Platelet specific promoters are insufficient to express protease activated receptor 1 (PAR1) transgene in mouse platelets. PLoS One 9:e97724|
Showing the most recent 10 out of 975 publications